vTv Therapeutics Posts a $0.94 Q3 GAAP Loss Per Share, 15 Cents Better Than Estimate

Cash and cash equivalents were $77.2 million on Sept. 30, 2026, compared with $88.9 million on Dec. 31, 2025.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.